Tag: archway

Basel, 01 August 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new, five-year efficacy, safety and durability data from the Phase III Portal study, a long-term extension of the Phase III Archway study, of Susvimo® (ranibizumab injection) for the treatment of people with nAMD.¹ Results show that Susvimo’s immediate and predictable durability was sustained over five years, with approximately 95% of people receiving treatment every six months requiring no supplemental treatment before each refill. The data were presented at the American Society of Retina Specialists (ASRS) 2025 Annual Meeting in Long Beach, California, United States.

Supplementing the notice of 17^th June 2025 on convening the meeting of bondholders of UAB “Orkela” (code 304099538, registered address at Jogailos st. 4, Vilnius, Lithuania; the Company) bond issue, ISIN code LT0000405961 (the Bonds) on 9 January 2025 at 10 AM, Vilnius time¹ (the Meeting), the trustee of the bondholders UAB "AUDIFINA" (code 125921757, registered address at A. Juozapavičiaus st. 6, Vilnius, Lithuania; the Trustee), has the following additional information about the upcoming Meeting.